1

Big Pharma Outlook 2026 Pharmavitae Analytics Report Extract

Datamonitor Healthcare Pharma intelligence I informa

Pharmavitae Analytics

Big Pharma Outlook 2026

As challenging trends in healthcare management crystallize, Big Pharma will need to tread carefully to ensure breakthroughs and innovations adequately

benefit all stakeholders across the value chain

Pfizer [1]

Sanofi [2]

GloxoSmithKline [3]

Roche [4]

AstraZeneca [5]

Novartis [6]

Merck & Co. [7]

Johnson & Johnson [8]

Eli Lilly [9]

Bristol-Myers Squibb [10]

06 07 08 09 10 11 12 13 14 15 16

[1] Pfizer

[2] Roche

[3] Merck & Co.

[4] Sanofi

[5] Johnson & John son

[6] Novartis

[7] GlaxoSmithKline

[8] AstraZeneca

[9] Bristol-Myers Squibb

[10) Eli Lilly

16 17 18 19 20 21 22 23 24 25 26

[1] Sanofi

[2] Eli Lilly

[3] AstraZeneca

[4] Merck & Co.

[5] Pfizer

[6] Johnson & Johnson

[7] Novartis

[8] GloxoSmithKline

[9] Bristol-Myers Squibb

https://pharmastore.informa.com/product/product-launch-commercialization-strategies/

The best coverage.The best forecasts.The best analysts.The best support.The Best of Health.

We’ve just made strategic investments in Datamonitor Healthcare to give you the best of health.

Introducing The New Datamonitor Healthcare.

We’ve quadrupled our business intelligence which covers more than 90% of prescription

medicines in the major markets. Our forecasts are tailored to your needs as events occur and

are powered by a new forecasting tool built in collaboration with a leading analytics technology provider. We’ve increased our global analyst resources by 300%, and Live Support

replies to your queries in real time, not hours, for the fastest support in the market.

Discover the best of health.

Visit: https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/datamonitor-healthcare to tour the new Datamonitor Healthcare with one of our representatives.

Request a live demo and see how The Best of Health supports smarter, faster decision-making.